Cargando…
Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls
BACKGROUND: Familial adenomatous polyposis (FAP) is a disease characterized by the development of hundreds to thousands of adenomatous polyps in the colorectum early in life. Virtually all patients with FAP will develop colorectal cancer before the age of 40 to 50 years, unless prophylactic colectom...
Autores principales: | van Heumen, Bjorn WH, Roelofs, Hennie MJ, te Morsche, René HM, Nagengast, Fokko M, Peters, Wilbert HM |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225600/ https://www.ncbi.nlm.nih.gov/pubmed/24245549 http://dx.doi.org/10.1186/1750-1172-8-181 |
Ejemplares similares
-
Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial
por: van Heumen, Bjorn WH, et al.
Publicado: (2013) -
Over-expression of COX-2 mRNA in colorectal cancer
por: Roelofs, Hennie MJ, et al.
Publicado: (2014) -
Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis
por: Friederich, Pieter, et al.
Publicado: (2011) -
Multiple Adenomatous Duodenal Polyposis
por: Zádorová, Zdena, et al.
Publicado: (2013) -
Increased epithelial cell proliferation in the ileal pouch mucosa of patients with familial adenomatous polyposis
por: Friederich, P., et al.
Publicado: (2007)